Eylea Growth Closes The Gap With Lucentis
by Pharmacy Life - Published on 03 May 2015
Sales of Bayer and Regeneron's eye disease therapy Eylea grew by two thirds in the first quarter of the year. The sales -
which topped €250m - mean that
Eylea can now compete with rival Lucentis, which is sold by Roche and Novartis.
Although Lucentis is still selling more than Eylea by value, it's beginning to show signs of weakness, with
Roche reporting US sales down nine per cent in the first quarter of the year to €394m and
Novartis - which sells it outside the US - posting a thirteen per cent decline to $539m.
Read more of this story which first appeared on PMiLive here.